Key Points
- Venrock Healthcare Capital Par bought 8,305 Lycia Therapeutics shares on November 2 at an average price of $26.95, spending about $223,820.
- After the purchase, Venrock held 6,858,542 shares, worth approximately $184.8 million. The transaction was part of a series of recent purchases, including nearly 1.95 million shares bought October 26.
- Lycia shares opened at $28.92 on Thursday, within a 12-month range of $22.19 to $36.49; Wall Street Zen recently raised its rating on the stock to “hold.”
Lycia Therapeutics, Inc. (NASDAQ:LYCA - Get Free Report) major shareholder Venrock Healthcare Capital Par bought 8,305 shares of the stock in a transaction dated Monday, November 2nd. The shares were purchased at an average cost of $26.95 per share, for a total transaction of $223,819.75. Following the completion of the purchase, the insider owned 6,858,542 shares in the company, valued at approximately $184,837,706.90. This represents a 0.12% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Friday, October 30th, Venrock Healthcare Capital Par bought 9,004 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $26.28 per share, for a total transaction of $236,625.12.
- On Thursday, October 29th, Venrock Healthcare Capital Par bought 1,000 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $26.33 per share, for a total transaction of $26,330.00.
- On Wednesday, October 28th, Venrock Healthcare Capital Par purchased 15,000 shares of Lycia Therapeutics stock. The stock was acquired at an average price of $25.45 per share, with a total value of $381,750.00.
- On Tuesday, October 27th, Venrock Healthcare Capital Par purchased 39,796 shares of Lycia Therapeutics stock. The stock was acquired at an average price of $26.62 per share, with a total value of $1,059,369.52.
- On Monday, October 26th, Venrock Healthcare Capital Par purchased 1,952,705 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $18.04 per share, with a total value of $35,226,798.20.
- On Friday, October 23rd, Venrock Healthcare Capital Par purchased 52,939 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $25.91 per share, for a total transaction of $1,371,649.49.
Lycia Therapeutics Price Performance
Shares of LYCA stock opened at $28.92 on Thursday. Lycia Therapeutics, Inc. has a 12-month low of $22.19 and a 12-month high of $36.49.
Wall Street Analyst Weigh In
Separately, Wall Street Zen raised Lycia Therapeutics to a "hold" rating in a research note on Saturday, October 31st.
Check Out Our Latest Stock Analysis on LYCA
Lycia Therapeutics Company Profile
(
Get Free Report)
Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company's approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.
Lycia's technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
